Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 14, 2026 at 3:50 AM GMT+3 3 min read

CLBT +3.15%

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary - Moby

Strategic Execution and Platform Evolution

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

The Board appointed Shiv Ramji as CEO to accelerate the transition toward a product-centric, cloud-native architecture capable of maximizing AI scalability.
Q2 ARR and revenue underperformed expectations due to the timing of a limited number of large transactions that slipped beyond the quarter's end.
Administrative and procurement hurdles related to the company's foreign entity status delayed several U.S. Federal and European government deals.
The shift toward larger, strategic opportunities involving cloud and AI has introduced more stakeholders and longer procurement cycles than legacy hardware-centric deals.
While the Insights digital forensic solution reached 65% of the installed base, the ARR uplift from pricing and footprint expansion was lower than anticipated, particularly in U.S. state and local government sectors.
Management is raising the standard for sales execution by implementing greater rigor around qualifying procurement milestones and executive sponsorship to improve forecasting precision.
The company is evolving from a digital forensics tool provider into a broader investigative intelligence platform, using a shared AI layer to compress investigative lifecycles.

Revised Outlook and Growth Assumptions

Full-year ARR guidance was lowered to $550 million–$560 million to reflect moderated Insights conversion pricing and greater prudence regarding deal timing.
Management removed potential upside from large, complex government deals from the forecast, citing unpredictable sales cycles in the current environment.
The company raised its full-year adjusted EBITDA target to $153 million–$159 million, reflecting disciplined headcount management and operational efficiency despite a 3-point FX headwind.
Growth expectations for Corellium were moderated to 1 to 2 percentage points, while Guardian, Pathfinder, and Genesis are expected to grow at the lower end of original mid-single-digit targets.
Management anticipates a step-up in profitability and free cash flow in 2027 as new products scale and current FX headwinds potentially subside.

Operational Risks and Structural Changes

Foreign entity status (FEP) requirements emerged as a new administrative barrier for cloud-based contracts with U.S. federal agencies, requiring the procurement of a master permit to expedite future orders.
New EU laws regarding freedom of information and data sovereignty created unforeseen legal review delays for cloud transitions in Germany and the U.K.
The launch of Genesis as a consumption-based product introduces a new revenue dynamic, allowing for in-cycle upgrades and product-led growth compared to fixed annual contracts.
Free cash flow performance in Q2 was impacted by specific deal structures and collections that arrived in the first week of July rather than June.

Q&A Session Insights

Status of slipped Q2 deals and sales cycle elongation

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management confirmed that no deals were lost to competitors; rather, they were delayed by approximately 6 weeks due to procurement complexities.
Of the business that slipped from Q2, $4 million has already closed and booked as of the earnings call date.

Drivers of lower pricing uplift during Insights migrations

The lower-than-expected pricing uplift is attributed to the maturity of current customer cohorts who were already well-deployed with legacy premium products.
Customers are becoming more conservative in their expansion posture at the time of migration, though gross revenue retention for Insights remains high.

Federal business outlook and FedRAMP competitive positioning

Cellebrite maintains the only FedRAMP High solution for digital forensics, which management views as a significant competitive moat given the long certification process for rivals.
The company has been shortlisted for its first-ever 9-figure program, signaling a shift toward much larger government contracts.

Early adoption trends for the new Genesis product

Genesis secured $400,000 in ARR within weeks of launch, with monetization pushing toward $1 million shortly after the quarter closed.
Adoption is spanning diverse segments including international leasing, state Attorneys General, and enterprise clients, utilizing an open-ended LLM integration model.